^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CRIP1 (Cysteine Rich Protein 1)

    i
    Other names: CRIP1, Cysteine Rich Protein 1, CRIP, Cysteine-Rich Protein 1 (Intestinal), Cysteine-Rich Intestinal Protein, Cysteine-Rich Heart Protein, Cysteine-Rich Protein 1, CRP-1, CRHP, CRP1, HCRHP
    11d
    CRIP1 knockdown enhances glycolytic dependence and increases sensitivity to 2-Deoxy-D-Glucose in acute myeloid leukemia. (PubMed, Mol Biol Rep)
    Our findings indicate that CRIP1 knockdown induces a glycolytic switch in AML cells, rendering them exquisitely sensitive to glycolytic inhibition by 2-DG. This suggests that CRIP1 status could serve as a biomarker for predicting response to metabolic therapies and highlights 2-DG as a promising therapeutic agent for a subset of AML characterized by glycolytic dependency.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • CRIP1 (Cysteine Rich Protein 1)
    |
    IACS-010759
    2ms
    A bortezomib resistance-related gene signature predicts prognosis, with ARID5B downregulation associated with poor overall survival in multiple myeloma. (PubMed, Discov Oncol)
    The BRGs signature is a reliable biomarker for predicting the prognosis of MM and helps optimize clinical decision-making for treatment, and identifies key gene ARID5B downregulation as an adverse prognostic factor in multiple myeloma.
    Journal • Gene Signature
    |
    LTBP1 (Latent-transforming growth factor beta-binding protein 1) • CRIP1 (Cysteine Rich Protein 1) • IFI16 (Interferon Gamma Inducible Protein 16) • ARID5B (AT-Rich Interaction Domain 5B)
    |
    bortezomib • doxorubicin hydrochloride • etoposide IV
    3ms
    A prognostic model for breast cancer survival based on PCD and m6A gene interactions. (PubMed, Front Immunol)
    A key finding from drug sensitivity analysis was that the high-risk group exhibited significantly increased sensitivity to several drugs, including CCT018159, rapamycin, vinblastine, metformin, and roscovitine. Moreover, the expression levels of SESN3, CRIP1, DPP4 and PIK3CA were significantly upregulated in breast cancer samples compared to control samples. This study constructed a risk model based on seven prognostic genes, offering new potential strategies for breast cancer therapy.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CRIP1 (Cysteine Rich Protein 1) • DAXX (Death-domain associated protein) • ANXA5 (Annexin A5)
    |
    sirolimus • metformin • vinblastine • seliciclib (CYC202)
    3ms
    Identification of a Treg-related gene signature for predicting prognosis and immunosuppression in skin cutaneous melanoma. (PubMed, Clin Exp Med)
    qRT-PCR and Western blot confirmed PTPRF, ULK1, TGM3, and CRABP2 were upregulated at both the mRNA and protein levels. These findings indicate that the Treg-related signature serves as robust prognostic biomarkers and may guide personalized immunotherapy in SCKM.
    Journal • Gene Signature • IO biomarker
    |
    HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • PTPRF (Receptor-type tyrosine-protein phosphatase F) • CRIP1 (Cysteine Rich Protein 1) • KHDRBS3 (KH RNA Binding Domain Containing, Signal Transduction Associated 3) • MIR375 (MicroRNA 375) • TFAP2A (Transcription Factor AP-2 Alpha) • TFAP2C (Transcription Factor AP-2 Gamma) • HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)
    3ms
    Single-cell hdWGCNA identifies ICI-related-colitis key CD8 + T cells linked to immunotherapy response and prognosis in colon cancer. (PubMed, Discov Oncol)
    CIC-key-CD8 T cells are pivotal in modulating the tumour microenvironment and can significantly impact the clinical outcome of colon cancer. Their high infiltration rate correlates with poor outcomes and immunotherapy resistance. Targeting these cells may improve therapeutic strategies for cancer immune checkpoint inhibitor treatments.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD40 (CD40 Molecule) • CRIP1 (Cysteine Rich Protein 1) • HSPA1A (Heat Shock Protein Family A (Hsp70) Member 1A)
    4ms
    PRMT1/PRMT5-Mediated Differential Arginine Methylation of CRIP1 Promotes the Recurrence of Small Cell Lung Cancer after Chemotherapy. (PubMed, Int J Biol Sci)
    Notably, combination therapy using PRMT5 inhibitor GSK3326595 along with cisplatin and etoposide significantly delayed the recurrence of SCLC. Our findings reveal the promoting effect of post-chemotherapy inflammation on tumor recurrence from an epigenetic perspective and provide a potential therapeutic strategy for SCLC treatment.
    Journal
    |
    PRMT1 (Protein Arginine Methyltransferase 1) • CRIP1 (Cysteine Rich Protein 1)
    |
    cisplatin • etoposide IV • pemrametostat (GSK3326595)
    5ms
    Cancer-associated fibroblasts shape the formation of budding cancer cells at the invasive front of human colorectal cancer. (PubMed, Commun Biol)
    In addition, we defined an 11-gene signature (TYK2, IL2RG, KRT17, HLA-B, NPPC, WIF1, IL32, B2M, CCND1, CRIP1, ITGB1), which characterizes cancer cells en route to metastasis and is associated with inferior outcomes. Collectively, our findings suggest that CAFs induce pro-invasive gene expression changes involved in EMT, ECM remodeling, and migration.
    Journal
    |
    CCND1 (Cyclin D1) • B2M (Beta-2-microglobulin) • HLA-B (Major Histocompatibility Complex, Class I, B) • KRT17 (Keratin 17) • TYK2 (Tyrosine Kinase 2) • IL32 (Interleukin 32) • CRIP1 (Cysteine Rich Protein 1) • WIF1 (WNT Inhibitory Factor 1) • ITGB1 (Integrin Subunit Beta 1) • IL2RG (Interleukin 2 Receptor Subunit Gamma)
    8ms
    The role and prognostic value of PANoptosis-related genes in skin cutaneous melanoma. (PubMed, Front Immunol)
    RT - qPCR validation confirmed significant expression differences of CD8A, ADAMDEC1, CD69, CRIP1, and BCL11B between SKCM and control samples. This study presents a robust prognostic model for SKCM based on PANoptosis - related genes, providing a theoretical foundation for SKCM treatment.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD69 (CD69 Molecule) • CCR7 (Chemokine (C-C motif) receptor 7) • BCL11B (BAF Chromatin Remodeling Complex Subunit BCL11B) • CRIP1 (Cysteine Rich Protein 1) • MIR330 (MicroRNA 330)
    9ms
    Improving predictive accuracy in multiple myeloma using a plasma cell profile derived from single-cell RNA sequencing. (PubMed, Haematologica)
    We further devised a simply digital PCR method for feasible quantifying the 7-gene signature, which still significantly differentiated the survival of MM patients and possesses considerable clinical application value. Overall, this integrated risk-scoring model derived from scRNA-seq data was significantly associated with a more advanced stage of myeloma patients, facilitating guided risk-adapted treatment strategies for such ultra-high-risk patients.
    Journal
    |
    CD74 (CD74 Molecule) • CCND2 (Cyclin D2) • CRIP1 (Cysteine Rich Protein 1) • LILRB4 (Leukocyte Immunoglobulin Like Receptor B4) • TUBA1B (Tubulin Alpha 1b)
    10ms
    Systematic Review of Relevant Biomarkers for Human Connective Tissue Repair and Healing Outcome: Implications for Understanding Healing Processes and Design of Healing Interventions. (PubMed, Adv Wound Care (New Rochelle))
    All of the 37 identified potential biomarkers demonstrated regulatory effects on CT repair and mediated healing outcomes. Notably, the identified biomarkers from human studies can potentially play an essential role in the development of targeted treatment protocols to counteract compromised healing and can also serve as predictors for detecting CT healing processes and long-term outcomes.
    Review • Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • HGF (Hepatocyte growth factor) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL10 (Interleukin 10) • MMP2 (Matrix metallopeptidase 2) • CCL19 (C-C Motif Chemokine Ligand 19) • FGF2 (Fibroblast Growth Factor 2) • TIMP1 (Tissue inhibitor of metalloproteinases 1) • VIM (Vimentin) • CSF2 (Colony stimulating factor 2) • TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9) • CRIP1 (Cysteine Rich Protein 1) • IL1B (Interleukin 1, beta) • IL1R1 (Interleukin 1 receptor, type I) • MMP1 (Matrix metallopeptidase 1) • MMP3 (Matrix metallopeptidase 3) • MMP7 (Matrix metallopeptidase 7) • POSTN (Periostin) • TIMP3 (TIMP Metallopeptidase Inhibitor 3)
    11ms
    Cysteine-rich intestinal protein family: structural overview, functional diversity, and roles in human disease. (PubMed, Cell Death Discov)
    The CRIP family is known to play an important role in cellular epithelial-mesenchymal transition, cell death, and tumor progression and participate in multiple signaling pathways. This article summarizes the roles and potential molecular mechanisms of the CRIP family in diseases, which will help to explore new research directions for this family and provide useful information for clinical applications such as disease diagnosis and treatment.
    Review • Journal
    |
    CRIP1 (Cysteine Rich Protein 1)
    1year
    CRIP1 inhibits cutaneous melanoma progression through TFAM-mediated mitochondrial biogenesis. (PubMed, Sci Rep)
    Our results suggest that CRIP1 inhibits the proliferation and invasive ability of cutaneous melanoma cells by suppressing TFAM-mediated mitochondrial biogenesis. Therefore, CRIP1 may be a potential therapeutic target for melanoma.
    Journal
    |
    CRIP1 (Cysteine Rich Protein 1) • TFAM (Transcription Factor A, Mitochondrial)